VitaScript Niacin Long Acting Vitamin B-3 500 mg (100 tablets)

$16.50

Niacin Long Acting tablets slowly release 500 mg of pure niacin. Sustained release niacin is better tolerated than regular crystalline high-potency niacin supplements. Niacin Long Acting is a scored uncoated tablet which can be broken in half when lower dosage is desired. Niacin Long Acting tablets may be a useful nutritional adjunct for individuals who wish to increase their intake of niacin without the uncomfortable side effects of skin flushing.

SKU: 10114 Categories: ,

Description

Niacin Long Acting tablets slowly release 500 mg of pure niacin. Sustained release niacin is better tolerated than regular crystalline high-potency niacin supplements. Niacin Long Acting is a scored uncoated tablet which can be broken in half when lower dosage is desired.

FUNCTIONS

Niacin (vitamin B3) occurs in the body as two metabolically active coenzymes, NAD (nicotinamide adenine dinucleotide) and NADP (NAD phosphate). The niacin coenzymes NAD and NADP have pervasive roles in energy-related and biosynthetic metabolic processes. At least 200 enzymes depend on these niacin cofactors. The NAD-dependent enzymes are involved in mostly catabolic, oxidative reactions that release energy from carbohydrate, fat, and protein, whereas the NADP-dependent enzymes more commonly function in biosynthetic pathways of such compounds as fatty acids and steroid hormones.

Independent of its functions as NAD or NADP, niacin is also involved in the regulation of normal blood lipoprotein and cholesterol levels. Dietary niacin is generally well absorbed and taken up by the liver which converts it to NAD and NADP. Any excess niacin is metabolized by the liver and excreted by the kidneys. Because the liver has a limited capacity to metabolize niacin, high doses of regular, crystalline niacin are often not well tolerated, causing vasodilatory side effects known as skin-flushing and itching. For maximum benefit and fewer side effects, Niacin Long Acting releases its niacin over a time frame of two to three hours. This way, the niacin is more efficiently utilized by the liver and more evenly distributed to peripheral tissues compared to crystalline niacin. For the same reasons, Niacin Long Acting can generally be used at somewhat lower doses than crystalline niacin supplements.

INDICATIONS

Niacin Long Acting tablets may be a useful nutritional adjunct for individuals who wish to increase their intake of niacin without the uncomfortable side effects of skin flushing.

FORMULA (WW #10114)

Each Scored Tablet:

  • Niacin………………………………………………………….500 mg

Other Ingredients: Vegetable stearin, cellulose, silicon dioxide, and magnesium stearate.

SUGGESTED USE

One tablet daily. Each tablet is a scored, uncoated tablet which can be broken in half if desired. This supplement is formulated to release niacin slowly over a 2 to 3-1/2 hour period to reduce the skin-flushing effect of this vitamin. As a general guideline when substituting Niacin Long Acting for crystalline niacin, use Niacin Long Acting at ½ to 2/3 of the level used for crystalline niacin.

SIDE EFFECTS

No adverse effects have been reported.

STORAGE

Store in a cool, dry place, away from direct light. Keep out of reach of children.

REFERENCES

  1. Alderman JD et al. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol 1989;64:725-729.
  2. Canner PL et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-1255.
  3. Colletti RB et al. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993;92:78-82.
  4. Keenan JM et al. Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med 1991;151:1424-1432.
  5. Lavie CJ et al. Marked benefit with sustained-release niacin therapy in patients with ‘isolated’ very low levels of high-density lipoprotein cholesterol and coronary artery disease. Am J Cardiol 1992;69:1083-1085.
  6. Probstfield JL. Nicotinic acid as a lipoprotein-altering agent: therapy directed by the primary physician. Arch Int Med 1994;154:1557-1559.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.